ModifiedUnitedHealthcarePolicy CS1O3KY.07

Prolotherapy and Platelet Rich Plasma Therapies (for Kentucky Only)

This policy governs coverage determinations for prolotherapy and platelet-rich plasma (PRP) therapies for members in Kentucky; it states these therapies are considered unproven and not medically necessary for any condition.

Policy Summary

PayerUnitedHealthcare

PolicyProlotherapy and Platelet Rich Plasma Therapies (for Kentucky Only)

Policy CodePolicy CS1O3KY.07

Change TypeHCPCS description revised

Effective DateFeb 1, 2025

Next Review Date

Key ActionVerify member-specific benefit plan and document prior conservative therapies and outcome measures when requesting authorization or reporting services.

SourceLink

POLICY UPDATE CHANGES

Revised description for HCPCS codes G0460 and G0465.

2therapies listed as not medically necessary

KYstate-specific application

0232T, G0460, G0465example codes listed

3-4small RCTs for prolotherapy

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

knee OA studies in network MA

Coverage Determination and Evidence Summary

Not Medically Necessary — PRP and Prolotherapy

The following therapies are considered unproven and not medically necessary for any condition or indication:

Not medically necessary therapies: Platelet-rich plasma

Listed as unproven and not medically necessary for any condition or indication.

Not medically necessary therapies: Prolotherapy

Listed as unproven and not medically necessary for any condition or indication.

Evidence summaries

Evidence summaries and situations summarized in the document where injectable therapies were studied

Knee osteoarthritis — evidence: Multiple RCTs and meta-analyses report that dextrose prolotherapy, PRP, mesenchymal stem cells, platelet-rich growth factor, and botulinum toxin A combined with exercise may improve short- and some long-term pain and function; studies are often small, heterogeneous, and have short follow-up periods. Network meta-analysis (Cheng 2024) ranked mesenchymal stem cells best for short-term pain and dextrose prolotherapy best for long-term relief.

Supported by Cheng 2024 and multiple systematic reviews.

Lateral epicondylosis — evidence: Meta-analysis (Zhu 2022) of 8 trials (354 patients) found dextrose prolotherapy reduced pain and improved function at 12 weeks versus active controls with clinically relevant margins; individual RCTs report prolotherapy may have longer-lasting benefit compared with corticosteroid in some studies.

Supported by Zhu 2022 and individual RCTs.

Rotator cuff and other tendinopathies — evidence: Randomized trials and systematic reviews report mixed results for dextrose prolotherapy and PRP in rotator cuff tendinopathy and other soft-tissue conditions; some trials show short-term improvements that are not sustained and heterogeneity in preparations and techniques limits conclusions.

Supported by Lin 2022, Giovannetti de Sanctis 2021, and multiple reviews.

Temporomandibular joint disorders — evidence: Systematic reviews and RCTs suggest autologous blood and dextrose prolotherapy can reduce TMJ dislocation episodes and improve pain/MIO in many patients, but trials are small and risk of bias varies.

Supported by Checinski 2023 and Sit et al. 2021.

Lower limb tendinopathies — evidence: Observational studies and systematic reviews suggest prolotherapy and sclerotherapy may reduce pain and neovascularization in Achilles and other lower limb tendinopathies; evidence includes uncontrolled cohorts and small RCTs with limited long-term data.

Supported by Bello Baez 2023, Morath 2018, Sanderson and Bryant 2015.

Evidence-based coverage context (no explicit policy criteria present)

Evidence summaries and contexts where injections were studied

Lateral epicondylosis: Randomized trials and comparative studies report corticosteroid, autologous blood, and prolotherapy can be effective short-term; some trials show prolotherapy/dextrose may have more durable effects at 3–6 months but sample sizes are small and imaging confirmation often lacking.

Evidence heterogeneous; see LE trials and reviews.

Rotator cuff tendinopathies: Several RCTs and systematic reviews report mixed results: some RCTs show short-term pain/function improvement with dextrose prolotherapy compared with saline or steroid; other studies find no difference vs placebo. Overall evidence limited by small trials and heterogeneity.

See Lin 2022, Giovannetti de Sanctis 2021, Bertrand 2016.

Temporomandibular joint disorders: Systematic reviews and RCTs suggest autologous blood and dextrose prolotherapy can reduce TMJ dislocation episodes and improve pain/MIO in many patients; however, trials are small and risk of bias varies across studies.

See Checinski 2023; Sit et al. 2021.

Evidence summaries for potential coverage criteria

Summary of evidence that could inform coverage determinations:

Knee osteoarthritis — mixed evidence: Multiple RCTs and meta-analyses report PRP may improve pain and function versus HA, corticosteroid, or placebo at some timepoints (notably 6–12 months) but high-quality large RCTs show no benefit; heterogeneity of PRP preparations and variable trial quality limit conclusions.

Supported by Qaio 2023, Bennell 2021, Filardo 2021, ECRI and Hayes reviews.

Lower limb tendinopathies: Evidence is mixed: some systematic reviews and RCTs show benefit (patellar, lateral epicondyle), while others show no clear advantage over non-PRP interventions; prolotherapy and sclerotherapy have limited evidence and require higher-quality trials.

Supported by Barman 2022, Migliorini 2022, Morath 2018.

Hip and other joints: Small RCTs and reviews provide insufficient high-quality evidence to conclude meaningful benefit of PRP over placebo or HA for hip OA or other joint indications at short-term follow-up.

See shoulder/hip reviews and AAOS guidance.

Evidence-based coverage considerations

Coverage considerations based on the summarized evidence in this document section

General prerequisites: Autologous PRP or prolotherapy should only be considered after documented failure of conservative treatments (e.g., structured physical therapy, activity modification, analgesics, and where applicable corticosteroid injection) and when baseline pain and functional scores are provided.

Supported by multiple reviews recommending conservative therapy first and documentation of baseline measures.

Knee — meniscal repair and patellar tendinopathy: Current evidence does not consistently demonstrate clinically meaningful benefit of PRP augmentation for meniscal repair or patellar tendinopathy compared with non-PRP injections; any potential benefit is limited and heterogeneous.

Supported by Migliorini 2022, Barman 2022, Hayes review.

ACL reconstruction: PRP may reduce some early postoperative pain or improve short-term function in specific applications (e.g., bone–patellar tendon–bone harvest sites) but does not consistently improve long-term stability or graft healing.

Supported by pooled ACLR studies and Hayes review.

Coverage-relevant evidence summaries

Evidence-based findings and implied coverage considerations for PRP across indications in these excerpts

Lateral epicondylitis (LE): Systematic reviews and meta-analyses report mixed results; some analyses show PRP meets MCID and yields long-term benefit versus steroid in some comparisons, but overall evidence is heterogeneous and low/very low certainty; PRP may be considered for persistent LE unresponsive to conservative care.

Supported by Masiello 2023, Niemiec 2022, Hayes 2022.

Foot/ankle adjunct to microfracture: Systematic reviews find no significant difference when adding PRP to arthroscopic microperforation for VAS and AOFAS, with any slight benefits not statistically significant; evidence insufficient.

Supported by Basciani 2024.

Low back pain (discogenic, facet, SIJ): Small RCTs and network meta-analyses report mixed outcomes; PRP may be equivalent to steroids or lidocaine short-term with inconsistent longer-term benefits; evidence limited by small sample sizes and heterogeneity.

Supported by Zhang 2024 and other small studies.

Coverage evidence groupings

Evidence-based summaries and guideline positions relevant to coverage decisions

Diabetic foot ulcers (DFUs): Systematic reviews and HTAs report low- to moderate-strength evidence that PRP added to conventional wound care may increase complete wound closure and shorten time to closure in DFUs, but heterogeneity and inconsistent reporting limit certainty.

Supported by ECRI, Hayes, Qu et al., Martinez-Zapata.

Venous leg ulcers (VLUs): Evidence is inconclusive for PRP in VLUs; available RCTs and reviews are insufficient to determine effect on healing outcomes.

Supported by ECRI and Hayes assessments.

Chronic wounds and pressure ulcers: Meta-analyses produce non-conclusive results overall; possible benefit for diabetic foot ulcers but insufficient evidence for other chronic wounds or pressure ulcers.

Supported by Martinez-Zapata and Qu et al.

The policy designates platelet-rich plasma (PRP) and prolotherapy as unproven and not medically necessary for any condition or indication. This statement is the primary coverage determination in the document and applies across indications unless otherwise specified by a member-specific benefit plan.

Systematic reviews and trials commonly cite important limitations that reduce confidence in conclusions, including small sample sizes, heterogeneity of injection techniques and PRP or dextrose concentrations, variable number/timing of injections, limited use of imaging to confirm diagnosis or guide injections, and generally short follow-up periods that limit assessment of durable benefit.

Across wound and musculoskeletal indications, studies frequently used different PRP preparation protocols and application methods, which along with inconsistent outcome measures and risk-of-bias concerns produces imprecision and inconsistency in pooled estimates and limits generalizability.

No explicit exclusion criteria (for example, specific diagnoses or service-level exclusions) are stated in the cited evidence excerpts; the document’s primary stance is a general designation of PRP and prolotherapy as unproven and not medically necessary rather than listing discrete procedural exclusions.

The excerpts do not specify age-, comorbidity-, or other patient-level exclusions. Where patient characteristics were relevant to trials (for example, Kellgren–Lawrence grade for knee OA or presence of peripheral arterial disease in DFU studies), those were used as enrollment criteria in research but are not presented here as explicit policy exclusions.

Routine use of PRP for tendinopathies is not recommended based on the available evidence. Multiple systematic reviews and comparative-effectiveness assessments conclude that evidence is insufficient or low/very low certainty to support routine PRP for common tendinopathies (including lateral epicondylitis, patellar, and Achilles tendinopathies), and benefits when reported are inconsistent and often not sustained long-term.

In the provided excerpts there are no additional explicit exclusions stated beyond the general not‑medically‑necessary designation; the policy focuses on evidence insufficiency rather than enumerating patient subgroups excluded from consideration.

NICE interventional guidance (2019) advises that autologous PRP gel for diabetic foot problems should not be offered outside of clinical trials and that PRP procedures generally should be used only with special arrangements for clinical governance, consent, audit, or research.

This Medical Policy is provided for informational purposes and does not constitute medical advice. Member-specific benefit plan documents govern coverage decisions and, in the event of conflict, the member-specific plan terms supersede this policy. Verify applicable federal or state mandates and the member’s plan before making coverage determinations.

Restating the policy position: PRP and prolotherapy are considered unproven and not medically necessary for any condition or indication as summarized in the coverage rationale.

Several authors and systematic reviewers emphasize the need for more rigorously designed, adequately powered, comparative randomized trials with standardized PRP/prolotherapy protocols and longer follow-up rather than making definitive practice recommendations based on the current heterogeneous evidence base.

A randomized controlled trial of dextrose prolotherapy for temporomandibular joint hypermobility found no statistically significant difference versus placebo at follow-up, indicating that dextrose prolotherapy was no more effective than placebo for this indication in that study.

Several high-quality randomized trials and meta-analyses report no clinically significant benefit of PRP compared with placebo or other injectables for some indications. For example, a large blinded RCT in mild-to-moderate knee osteoarthritis found no difference in 12‑month pain or structural outcomes between leukocyte-poor PRP and saline placebo; other trials and meta-analyses similarly report mixed or null results across indications.

Use of PRP for many ligament and tendon injuries and as a routine conservative treatment option is not established. Comparative-effectiveness reviews identify limited, inconsistent, or low-quality evidence across ACL reconstruction, patellar tendinopathy, and other knee ligament/tendon indications, precluding a clear demonstration of clinically important benefit.

Multiple systematic reviews and health‑technology assessments conclude the evidence is inconclusive or of low to very low certainty for many musculoskeletal and wound indications. This low certainty is driven by risk of bias, imprecision, inconsistency, and heterogeneity in preparation and administration methods across studies.

Professional guideline positions generally advise caution. The American Association of Hip and Knee Surgeons and American College of Rheumatology recommend against routine use of biologic therapies including PRP for advanced hip/knee arthritis, and PRP is strongly recommended against for knee and/or hip osteoarthritis in the ACR guidance — supporting conservative use or restriction for these indications.

Provider Requirements, Documentation, and Authorization Considerations

Prior Authorization

Prior Authorization and Benefit Verification

Prior authorization may be required for certain indications, particularly diabetic foot ulcers (DFU) and other wound indications where evidence and protocols are heterogeneous. Verify prior authorization requirements with the member's specific plan before scheduling or performing PRP or prolotherapy procedures.

Prior authorization likely for DFU and some wound/limited-evidence indications; check member plan
Member-specific benefit verification required — plan terms govern coverage and mandates
When in doubt, obtain medical review/authorization for PRP or prolotherapy for wound-related indications

Denial Risk

PRP and prolotherapy are considered unproven and not medically necessary for covered services in this policy's Coverage Rationale. Claims for PRP or prolotherapy may therefore be at higher risk of denial; secure documentation and prior authorization where appropriate if pursuing coverage exceptions or trial/registry pathways.

Procedure and Billing Codes

Listed procedure/CPT/HCPCS codesmixed

0232T	Injection(s), platelet rich plasma, any site, including image guidance, harvesting and preparation when performed.
G0460	Autologous platelet rich plasma (PRP) or other blood-derived product for nondiabetic chronic wounds/ulcers (includes administration, dressings, phlebotomy, centrifugation or mixing, and all other preparatory procedures, per treatment).
G0465	Autologous platelet rich plasma (PRP) or other blood-derived product for diabetic chronic wounds/ulcers, using an FDA-cleared device for this indication (includes administration, dressings, phlebotomy, centrifugation or mixing, and all other preparatory procedures, per treatment).
M0076	Prolotherapy.
P9020	Platelet rich plasma, each unit.

Applicable HCPCS codes referenced in historyHCPCS

G0460	HCPCS code description revised (see policy supporting information)
G0465	HCPCS code description revised (see policy supporting information)

Clinical Background and Definitions

Prolotherapy involves injection of agents such as hypertonic dextrose, saline, or local anesthetics into periarticular, tendon, or ligamentous tissues with the intent of stimulating a mild inflammatory response to promote tissue repair. Proposed mechanisms include induction of local growth factors and reparative processes; however, clinical protocols and substances used vary across studies.

Prolotherapy — definition

DefinitionInjection of substances (e.g., dextrose, saline, sarapin, procaine, lidocaine) to stimulate the body's healing mechanisms to promote growth of normal cells/tissues in injured ligaments, tendons, or joints; includes variants such as growth factor injection, growth factor stimulation, and inflammatory prolotherapy.

MechanismDirected injections produce a mild inflammatory response intended to encourage growth of new ligament or tendon fibers, tightening and strengthening the weakened structure.

VariationsMay include growth factor injection prolotherapy, growth factor stimulation prolotherapy, and inflammatory prolotherapy; newer formulas sometimes incorporate PRP or autologous stem cell sources.

Policy Revisions

2025-02-01codes_revisionLatest

Applicable HCPCS codes G0460 and G0465 descriptions were revised and the policy's supporting information (Clinical Evidence, FDA, References) was updated; previous policy version CS103KY.06 was archived.

This policy is informational and does not replace the member-specific benefit plan. Supporting information and code descriptions were updated in the policy history; check the member’s plan and any applicable mandates before applying this policy to coverage determinations.

Policy Summary

PayerUnitedHealthcare

PolicyProlotherapy and Platelet Rich Plasma Therapies (for Kentucky Only)

Policy CodePolicy CS1O3KY.07

Change TypeHCPCS description revised

Effective DateFeb 1, 2025

Next Review Date

Key ActionVerify member-specific benefit plan and document prior conservative therapies and outcome measures when requesting authorization or reporting services.

SourceLink

On This Page

Lower limb tendinopathies (Achilles, ankle): Observational studies and systematic reviews suggest prolotherapy and sclerotherapy may reduce pain and neovascularization in Achilles tendinopathy; evidence includes uncontrolled cohorts and small RCTs with limited long-term data.

See Bello Baez 2023, Morath 2018, Sanderson and Bryant 2015.

General evidence limitations: Across indications, lack of standardization of PRP preparation, variable injection protocols, small sample sizes, and short follow-up are recurrent limitations that impede definitive coverage recommendations.

Consistent theme across multiple systematic reviews and HTAs.

Plantar fasciitis and Achilles tendinopathy: Some RCTs and meta-analyses suggest PRP may be superior to corticosteroid for mid-term outcomes in plantar fasciitis; evidence for Achilles tendon is limited and inconclusive.

Supported by Kumar 2024, Fei 2021, Hayes review.

Shoulder — rotator cuff: PRP may provide short-term pain reduction and improved short-term function and may reduce retear rates after rotator cuff repair in some meta-analyses, but benefits generally do not persist long-term and evidence quality is low to very low.

Supported by multiple meta-analyses and Hayes/Evidence reviews.

Lateral epicondylitis: Comparative studies show mixed results with some longer-term benefit of PRP or prolotherapy versus corticosteroid, but overall evidence is heterogeneous and does not support routine use.

Supported by Masiello 2023, Zhu 2022, Niemiec 2022.

Wounds (DFU, pilonidal, grafts): Systematic reviews and HTAs (Hayes, ECRI) suggest low- to moderate-strength evidence that PRP may improve healing and increase complete wound closure in diabetic foot ulcers compared with standard care, but heterogeneity in protocols and populations limits certainty.

Supported by Hayes 2022 and ECRI assessments.

Orthopedic indications (knee, hip, shoulder): Guideline recommendations vary: AAOS states PRP may reduce pain/improve function in knee OA (low-quality evidence) but does not recommend for glenohumeral OA; AAHS and ACR advise against routine use for advanced hip/knee OA.

Supported by AAOS, AAHKS, ACR, VA/DoD statements.

PRF for soft tissue regeneration: Clinical studies report positive wound-healing signals for platelet-rich fibrin (PRF) in many trials, but RCT evidence is conflicting and control quality is variable, limiting firm conclusions.

Supported by Miron et al. and related reviews.

Denial risk is elevated because PRP and prolotherapy are listed as not medically necessary in this policy
If provider believes an exception is clinically justified, submit comprehensive clinical documentation with any prior authorization request

Note

Authorization and Billing Triggers — Absence of Explicit Criteria

Some source materials (systematic reviews, technology assessments) do not specify administrative prior-authorization triggers or explicit billing denial criteria. Absence of an explicit trigger in the evidence does not eliminate payer-specific authorization or coverage rules—verify with the member plan.

No universal administrative prior-authorization requirement is specified in the evidence summaries — payer rules may differ
Lack of an explicit denial trigger in the clinical literature does not guarantee coverage

Note

Evidence Quality and Coverage Impact

Evidence quality is variable and often low to very low; this can materially affect coverage decisions. Where evidence is insufficient or of low quality, payer review or requirement for special governance (research/registry) is commonly recommended.

Low or inconsistent evidence may lead to noncoverage or requirement for additional review
Off-label uses should be clearly documented and may require special review

Prior Authorization

Special Arrangements and Clinical Governance

For indications with limited or uncertain evidence (e.g., KOA, tendinopathies, some wound types), consider special arrangements such as use only within clinical trials, registries, or with clinical governance, informed consent, and audit — consistent with NICE recommendations for PRP in KOA.

Recommend use within clinical research, registry, or under special governance when pursued for limited-evidence indications
Document informed consent discussing limited/uncertain benefit

Documentation Required

Required Documentation Elements

Trials and systematic reviews uniformly emphasize the need to document prior conservative therapy failure, baseline and follow-up clinical measures, and procedural details (PRP preparation, number/timing of injections, image guidance). Include these elements when submitting charts or authorization requests.

Document failure of conservative therapy (PT, NSAIDs, orthotics, off-loading, standard wound care) prior to PRP/prolotherapy
Provide validated baseline and follow-up outcome measures where applicable (e.g., WOMAC, KOOS, VAS, AOFAS, IKDC, Lysholm, PRTEE, VISA-P, CMS, ASES)
Record imaging findings and radiographic grade (e.g., Kellgren-Lawrence for knee OA) when used in trials
Detail PRP/prolotherapy preparation protocol, platelet concentration if available, volume, sterility, number and timing of injections, and use of image guidance

Step Therapy

Conservative Therapy Requirements

Conservative therapy is commonly required before PRP or prolotherapy in clinical trials and reviews. Ensure documentation of prior conservative management and its duration when seeking coverage or submitting appeals.

Document prior conservative measures attempted (e.g., physical therapy, activity modification, bracing, injections such as corticosteroid or HA where appropriate, standard wound care and dressings for DFU/VLU)
Indicate duration and objective response to conservative care

Billing Rule

Comparative Evidence and Prior Treatments

Comparative studies frequently evaluate PRP against other injectable options (hyaluronic acid, corticosteroids), whole blood, dextrose prolotherapy, or placebo. When applicable, include prior responses to these comparators in the clinical record.

If prior HA or steroid injections were given, document dates, preparations, and responses
Include rationale for choosing PRP/prolotherapy over alternative injectable therapies

Prior Authorization

Member Benefit Verification

Member-specific benefit verification is required. This policy assists interpretation of standard plans; the member's benefit plan document and any applicable federal/state mandates control coverage decisions.

Always check member-specific plan, state mandates, and employer group exceptions
When conflicts exist between this policy and the member plan, the member plan governs

Platelet-rich plasma (PRP) — definition

DefinitionAn autologous blood preparation with a high platelet concentration and concentrated platelet-derived growth factors and cytokines intended to stimulate regeneration and promote tissue repair.

Preparation variabilityPRP preparations are not standardized and exhibit wide variability in platelet and white blood cell concentrations; clinical impact of this variability is unclear.

Use contextPRP may be introduced into tissues with low healing potential to deliver growth factors that potentially stimulate regeneration and tissue repair.

Dextrose prolotherapy (DPT) — definition

DefinitionInjection of hypertonic dextrose solution into or around joints or tendinous insertions intended to reduce pain and improve function; studied at varying concentrations and injection techniques.

Evidence examplesStudied in knee osteoarthritis trials and meta-analyses (Wee et al. 2021; Cheng 2024) and in lateral epicondylosis (Zhu 2022) showing short-term improvements in some trials.

LimitationsHeterogeneity in concentrations, injection sites, techniques, and small sample sizes limit definitive conclusions about efficacy.

Hyaluronic acid (HA) — definition

DefinitionIntra- or periarticular injection of hyaluronic acid used for soft tissue and joint indications, studied for short- and mid-term pain relief across various soft tissue indications.

Indications studiedEvaluated for rotator cuff disease, elbow pain, ankle sprains, Achilles and patellar tendinopathy, trigger finger, and other soft tissue conditions.

Evidence summaryMeta-analysis of 19 RCTs (n=1,629) found HA provided short-term and some mid-term pain benefit versus placebo and active comparators, though heterogeneity limits conclusions.

Mesenchymal stem cell injection — definition

DefinitionIntra-articular cellular therapy using mesenchymal stem cells (autologous or allogeneic) evaluated as an adjunct to exercise or other treatments for knee osteoarthritis.

Evidence contextIn a 2024 network meta-analysis (Cheng et al.), mesenchymal stem cell injection ranked highest for short-term pain reduction among agents combined with exercise.

LimitationsAvailable trials are often small and heterogeneous; further research needed to confirm clinical relevance and long-term benefit.

Hypertonic dextrose prolotherapy — definition

DefinitionInjection therapy using concentrated glucose solutions (e.g., 12.5%–25% or 20%) into peri- or intra-tendinous or bursal locations aiming to reduce pain and improve function.

Example protocolsStudies have used concentrations such as 20% dextrose for rotator cuff tendinopathy and 25% for intratendinous Achilles prolotherapy with repeated injections over weeks.

Observed effectsTrials report short-term pain and functional improvements in some tendinopathies, but effects often diminish over time and studies lack standardization.

Autologous blood (AB) injection — definition

DefinitionInjection of the patient’s own (autologous) blood into a joint or periarticular tissues; used in trials for TMJ hypermobility and some tendinopathies.

Clinical findingsSystematic reviews of AB injection for TMJ hypermobility report reductions in dislocation episodes and improvements in pain and range of motion in many patients, though trials vary in design.

Study limitationsHeterogeneity in number of injections, control groups, and risk-of-bias concerns limit definitive conclusions about single administration effectiveness.

PDRN prolotherapy — definition

DefinitionProlotherapy using polydeoxyribonucleotide (PDRN) solutions injected into tendinous tissues as a variant of prolotherapy intended to support tendon healing.

EvidenceCase series and retrospective studies report improvements in pain and function (e.g., chronic rotator cuff tendinopathy), but randomized comparative trials are lacking.

LimitationsAvailable data are limited by observational designs and lack of randomized controls; further RCTs with imaging outcomes are recommended.

Leukocyte-poor vs leukocyte-rich PRP — definition

DefinitionPRP formulations can be classified by leukocyte content: leukocyte-poor PRP (LP-PRP) and leukocyte-rich PRP (LR-PRP); leukocyte content may influence local adverse events and possibly efficacy.

Evidence implicationsSome systematic reviews and trials specifically compare LR-PRP versus LP-PRP and report improvements across PROMs with both types, but heterogeneity prevents firm conclusions about superiority.

Reporting recommendationTrials and reviews emphasize documenting PRP preparation method (leukocyte content, platelet concentration) because variability affects interpretation of results.

Kellgren-Lawrence grade — definition

DefinitionA radiographic grading system for knee osteoarthritis (Kellgren–Lawrence grade); commonly used enrollment criterion in trials (e.g., Bennell et al. enrolled patients with grade 2 or 3 disease).

Use in trialsUsed to define mild to moderate radiographic KOA populations for PRP RCTs and to standardize patient selection in studies.

LevelsGrades range from 0 (no radiographic change) to 4 (severe osteoarthritis), with grade 2–3 representing mild to moderate disease commonly included in trials.

PRP (general) — definition

DefinitionAutologous platelet-rich plasma (PRP) injections used to treat tendinopathies and augment surgical repairs; PRP contains concentrated platelets and growth factors intended to promote repair.

Variability notePreparations and application methods vary widely across studies (platelet counts, leukocyte content, volume, injection timing and number), limiting comparability of outcomes.

Clinical contextsEvaluated across indications including knee OA, tendinopathies, rotator cuff repair adjuncts, plantar fasciitis, and wound healing (DFUs, VLUs), with mixed results.

AOFAS score — definition

DefinitionAmerican Orthopaedic Foot and Ankle Society (AOFAS) score — a clinician-reported outcome measure assessing pain, function, and alignment used in foot and ankle studies (e.g., plantar fasciitis trials).

UseReported as an outcome metric in RCTs and meta-analyses comparing PRP and other injections for plantar fasciitis and foot/ankle conditions.

InterpretationHigher AOFAS scores indicate better function; used alongside VAS and other PROMs to assess treatment effect in foot/ankle studies.

MCID — definition

DefinitionMinimal clinically important difference (MCID) — the smallest change in a patient-reported outcome measure perceived as important by patients; used in PRP/lateral epicondylitis analyses to interpret clinical relevance.

ApplicationAnalyses compare mean PROM changes to established MCID thresholds to determine whether observed improvements are clinically meaningful, not just statistically significant.

ExampleNiemiec et al. used MCID values to assess whether PROM improvements after PRP for lateral epicondylitis exceeded clinically important thresholds at multiple follow-up timepoints.

Platelet-rich fibrin (PRF) — definition

DefinitionPlatelet-rich fibrin (PRF) — an autologous platelet product used for soft tissue regeneration and wound healing; reported in clinical studies though methods and controls vary.

Evidence summarySystematic review (Miron et al. 2017) found that 58% of clinical studies reported positive wound healing events with PRF but noted conflicting RCT findings and lack of appropriate controls.

Research needAuthors recommend better-controlled RCTs with appropriate comparators to evaluate PRF’s regenerative potential for soft tissue wound healing.

Prolotherapy — alternate entry

Alternate definitionInjection-based therapy using agents such as dextrose intended to stimulate tissue repair; agents used may be FDA-approved for injection but frequently used off-label for prolotherapy indications.

MechanismDirected injections 'trick' the body to repair by causing a localized mild inflammatory response that encourages new tissue formation and strengthening.

Variants and adjunctsMay incorporate PRP or autologous stem cell sources; physicians tailor formulations and techniques according to patient need.

External evidence sources

NICENational Institute for Health and Care Excellence (NICE) guidance cited (e.g., IPG637 and NG19) — NICE recommends caution and, for some indications like diabetic foot problems, advises PRP only in research contexts.

HayesHayes Health Technology Assessments cited for comparative effectiveness reviews of PRP across indications (rotator cuff, knee, tendinopathies, wounds).

Other sourcesAdditional external evidence includes ECRI assessments and professional society guidance (AAOS, ACR, AAHKS, VA/DoD) cited in the policy references to inform coverage considerations.